Utility of Lung Ultrasound in COVID-19: A Systematic Scoping Review

15/6/2020

Primary Author
Michael M TRAUER, MBBS, FRCEM, PgCert (Medical Ultrasound), MMus, Consultant in Emergency Medicine1, 2

Contributing Authors
Ashley MATTHIES, MBBS, BSc3, Specialist Registrar in Emergency Medicine

Nick MANI, MBBS, BMedSci, MBChB, PgCertSurgSci, PgCertMedRes, PgCertMedEd, MRCS, MRCEM, PgCert Medical Ultrasound, Specialist Registrar in Emergency Medicine

Cian MCDERMOTT, MBBS, FRCEM, FACEM, CCPU, Consultant in Emergency Medicine & Director of Emergency Ultrasound Education5, 6

Robert JARMAN, MBBS, MSc (Medical Ultrasound), FRCS(Ed), FRCEM(UK), FRCP(Ed), CFEU, Consultant in Emergency Medicine, Visiting Professor and MSc Point-of-care Ultrasound Lead2, 7

1. Guy’s and St Thomas’ NHS Foundation Trust, UK
2. University of Teesside, Middlesbrough, UK
3. Homerton University Hospital NHS Foundation Trust, UK
4. Leeds Teaching Hospitals NHS Trust, UK
5. Mater University Hospital, Dublin, Ireland
6. Pillar Centre for Transformative Healthcare
7. Royal Victoria Infirmary, Newcastle upon Tyne, UK

Authors’ contributions

Writing of manuscript (MT, AM)
Critical review of manuscript (NM, CM, BJ)

All correspondence

Dr Michael Trauer, Consultant, Emergency Department, Guy’s and St Thomas’ NHS Foundation Trust, London SE1 7EH, London, UK. michael.trauer@gstt.nhs.uk, Twitter: @michael_trauer

All authors read and approved the final manuscript. No sources of funding were used to assist in the preparation of this study. Each author certifies that he has no commercial associations that might pose a conflict of interest. We certify that this research was conducted in conformity with ethical principles of our institutions. The text and tables have not been previously published and reproduced from another source.
ABSTRACT

Lung ultrasound (LUS) has an established evidence base and has proven useful in previous viral epidemics. An understanding of the utility of LUS in COVID-19 is crucial to determine its most suitable role based on local circumstances. A scoping review was thus undertaken to explore the utility of LUS in COVID-19 and guide future research.

33 studies were identified which represent a rapidly expanding evidence base for LUS in COVID-19 however the quality of the included studies was relatively low. LUS certainly appears to be a highly sensitive and fairly specific test for COVID-19 in all ages and in pregnancy, however its accuracy may be influenced by various factors including disease severity, pre-existing lung disease, scanning protocol, operator experience, disease prevalence and the reference standard.

High quality research is needed in various fields including: diagnostic accuracy in undifferentiated patients; triage and prognostication; monitoring progression and guiding interventions; persistence of residual LUS findings; inter-observer agreement; and the role of contrast-enhanced LUS.

Keywords:

- Lung ultrasound
- PoCUS
- COVID-19
INTRODUCTION

Rationale

Coronavirus Disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and was declared a global pandemic on the 11th March 2020 by the World Health Organisation. As of the 10th of June, there have been over seven million confirmed cases and over 400,000 deaths [1].

The evidence base for lung ultrasound (LUS) is well established. In 2008, LUS was found to have an accuracy of greater than 90% for some of the most common causes of dyspnoea [2]. In 2011, an international, evidence-based, consensus statement recommended its use in pneumothorax, interstitial syndrome, consolidation and effusion [3]. In 2015, a prospective study of over a thousand patients found incorporation of LUS into clinical assessment significantly improved sensitivity (97%) and specificity (97.4%) for acute heart failure [4]. And in 2018, a meta-analysis of over five thousand patients found LUS to be 92% sensitive and 93% specific for community-acquired pneumonia [5].

LUS has also proven useful during recent viral epidemics. In the 2009 influenza (H1N1) epidemic, LUS was found to be accurate in differentiating viral and bacterial pneumonia [6], and during the avian influenza (H7N9) epidemics LUS was found to be superior to CXR (sensitivity 94%, specificity of 89%) [7,8].

In admitted patients with COVID-19, CXR has a reported sensitivity of between 59% and 69% [9,10]. In ambulatory patients with symptomatic COVID-19, CXR sensitivity has been reported at 42% [11].

The sensitivity of PCR for COVID-19 has been estimated at 70% [12] and depends upon factors including the quality of sampling and stage of illness.
CT of the thorax is highly sensitive for COVID-19 \cite{13} however LUS has several logistical advantages. The capacity to perform routine CT in suspected COVID-19 may become overwhelmed if large numbers of patients attend hospital. LUS has also been shown to reduce healthcare worker exposure to COVID-19 by reducing the intra-hospital transfers associated with conventional imaging \cite{14}. Other advantages of LUS over CT include reduced cost, repeatability, lack of radiation exposure and rapid image acquisition time \cite{15}.

LUS has been shown to improve diagnostic accuracy in patients who present with acute respiratory symptoms \cite{16} and is increasingly used by frontline clinicians who assess these patients. Ultrasound machines continue to improve in quality, affordability and portability \cite{17} and new technologies such remote teleguidance have the potential to further extend the accessibility of point-of-care ultrasound.

The LUS findings in COVID-19 are well described and include B lines, pleural line abnormalities and consolidation \cite{18}. However the most suitable role for LUS in COVID-19 is still unclear. Various roles have been proposed including triage, diagnosis, prognostication, severity scoring, monitoring progression, and guiding interventions \cite{19}. An understanding of the utility of LUS is crucial to determine its most suitable role in COVID-19 based on local circumstances.

**Objectives**

To review the evidence of the utility of LUS in COVID-19 and guide future research

- **Population:** Patients with suspected or confirmed COVID-19
- **Concept:** The utility of LUS
- **Context:** Clinical management

**METHODS**

**Protocol and registration**
The protocol was drafted in line with PRISMA [20] and registered on https://figshare.com on 13/6/2020 (10.6084/m9.figshare.12478820)

**Inclusion criteria:**

- Patients of any age with suspected or confirmed COVID-19
- Explores the utility of LUS in COVID-19
- Trials or case series (prospective or retrospective)

**Exclusion criteria:**

- Case reports and recommendations
- Non-English language

**Information sources**

Traditional online databases were searched including: Medline, Embase, SCOPUS, The Cochrane Library, The TRIP database, Google Scholar and www.clinicaltrials.gov.

Given the dynamic nature of the pandemic, other less traditional sources were also searched including point-of-care ultrasound (PoCUS) websites, specialty college websites, pre-publication websites and social media platforms (see Appendix I).

**Search strategy**

An initial search strategy was formulated by MT and reviewed by AM using the PRESS checklist [21]. This initial search was performed on two databases (Medline and Embase) (See Appendix II).
Keywords were identified from the above abstracts and another search was performed of all relevant databases (See Appendix III).

Selection of sources
A screening and selection tool was applied to the identified studies by two independent reviewers (MT & AM) with a third reviewer (NM) available to resolve disagreements (See Appendix IV).

The reference lists from these included studies were then reviewed for further relevant studies. The authors of the included studies were contacted regarding relevant unpublished or recently published evidence.

Data items
Data was extracted on study design, numbers of participants, population, and data relating to the utility of LUS in COVID-19.

Synthesis of results
Given the heterogeneity of the data, findings are described in a narrative style.

RESULTS
Selection of sources of evidence
A flow diagram in line with PRISMA [20] is presented in Figure 1 and displays the number of studies screened, excluded and assessed.
Figure 1. PRISMA Flow diagram

Records identified through database searching (n=227)  Additional records identified through other sources (n=2)

Records after duplicates removed (n=131)

Records screened (n=131)  Records excluded (n=90)

Full-text articles assessed for eligibility (n=41)  Case reports, recommendations (n=8)

Studies included in qualitative synthesis (n=33)

Characteristics of sources of evidence

A total of 33 studies were identified from countries including China, Italy, Spain, France and the USA. 17 were single-centre, three were multi-centre and the numbers of participants in each study ranged from three to 107.

The topics explored in each study are summarised in Table 1. The characteristics of each included study are summarised in Appendix V.
<table>
<thead>
<tr>
<th>Topics explored</th>
<th>Studies identified</th>
</tr>
</thead>
<tbody>
<tr>
<td>Description of LUS findings</td>
<td>5</td>
</tr>
<tr>
<td>Comparison of LUS to a reference standard</td>
<td>9</td>
</tr>
<tr>
<td>Serial LUS imaging</td>
<td>2</td>
</tr>
<tr>
<td>Technological innovation</td>
<td>4</td>
</tr>
<tr>
<td>Special groups</td>
<td>7</td>
</tr>
<tr>
<td>Reviews</td>
<td>6</td>
</tr>
<tr>
<td>Total</td>
<td>33</td>
</tr>
</tbody>
</table>

**Studies that describe LUS findings in COVID-19**

The LUS findings in COVID-19 have already been well described and consist of B lines, pleural line abnormalities and consolidations usually without pleural effusion \([18, 22, 23, 24, 25]\). Mohamed et al. \([26]\) performed a meta-analysis of such studies (seven studies, 122 patients) and found B lines were the most common and consistent finding but other LUS findings had a high degree of heterogeneity.

**Comparison of LUS to a reference standard (CT)**

In non-peer reviewed data from Tung-Chen et al. \([27]\), 51 adults presented to ED with confirmed or suspected COVID-19, both received CT and LUS and 67% were admitted. LUS was performed by a single, experienced operator blinded to CT and clinical findings. CT was suggestive of COVID-19 in 37 patients and all were identified by LUS (sensitivity 100%, specificity 79%). The area under the ROC curve was greater for LUS (86%) than for PCR (63%) for detecting CT abnormalities.

In non-peer reviewed data from Hankins et al. \([28]\), 49 patients over the age of 14 and without underlying lung disease attended ED with symptoms of COVID-19. Compared to CT, LUS
had a sensitivity and specificity of 100% and 80% respectively when performed by the
treating clinician however this fell to 92% and 37% when the images were reviewed in
isolation by an independent reviewer. Compared to CT, the sensitivity of CXR and crackles
on auscultation was 25% and 8% respectively.

In Yang et al. [29], 29 adult patients with confirmed COVID-19 received simultaneous LUS
and CT and the lung fields were divided into 12 regions. 63% of regions displayed abnormal
findings on LUS (3 or more B lines, consolidation or pleural effusion) compared to 39% of
regions on CT (ground-glass opacity, consolidation or pleural effusion). The authors
concluded that LUS was more sensitive at identifying the above findings than CT.

In non-peer reviewed data from Benchoufi et al. [30], 107 adult patients attended ED with
confirmed or suspected COVID-19, all received both CT and LUS and CT was typical for
COVID-19 in 86. When LUS was considered as a four-category ordinal scale of severity,
there was moderate agreement with CT, kappa 0.52 (0.38-0.66), however when this was
reduced to a binary outcome (normal vs pathologic) there was strong correlation (sensitivity
95%, specificity 83%).

In Lu et al. [31], 30 adult patients admitted with confirmed COVID-19 received both LUS and
CT. The ability of LUS to predict the severity of COVID-19 using CT as the reference
standard was assessed. The diagnostic accuracy of LUS for no, mild, moderate and severe
disease was 93%, 77%, 77% and 93% respectively.

In Poggliali et al. [32] and Lyu et al. [33], a total of 20 adult patients received both LUS and CT
and the authors noted a strong correlation between LUS and CT.

**Comparison of LUS to a reference standard (PCR)**
In Peyrony et al. [34], 47 patients presented to an Emergency Department with suspected COVID-19 and received LUS. The presence of bilateral B lines had a sensitivity and specificity of 77% and 89% respectively.

In Bar et al. [35], 100 adults presented to an Emergency Department with suspected COVID-19. 31 were PCR positive but CT results were not recorded. The combination of qSOFA (quick sequential organ failure assessment) score and LUS gave an area under the ROC curve of 0.82 with sensitivity and specificity of 97% and 62% respectively.

**Special groups**

Four paediatric studies were identified comprising 26 patients, all admitted with confirmed COVID-19 and ranging from neonatal to 15 years of age. In Musolino et al. [36], Feng et al. [37] and Gregorio-Hernandez et al. [38], all 18 patients (ten children and eight neonates) demonstrated LUS findings. In Denina et al. [39], five of the eight children demonstrated LUS findings (one of four children with mild disease but all four cases of moderate to severe disease).

Three obstetric studies were identified comprising 16 patients, all admitted with confirmed COVID-19. In Buonsenso et al. [40] and Giannini et al. [41], all eight patients demonstrated typical LUS findings. In Yassa et al. [42], seven of the eight women demonstrated LUS findings and LUS changed clinical management in 87.5% of cases.

**DISCUSSION**

**Methodology**

There were various issues regarding the methodology of the included studies including convenience sampling, unrepresentative populations (often only admitted patients), lack of power calculations, variability of index test (operator experience, scanning protocol), variability of reference standard (CT, single PCR test, multiple PCR tests) and...
reproducibility. A summary of the levels of evidence of the included studies according to the Oxford centre for evidence-based medicine [43] is displayed in table 2.

**Table 2.**

<table>
<thead>
<tr>
<th>Level of Evidence</th>
<th>Number of studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>1a</td>
<td>0</td>
</tr>
<tr>
<td>1b</td>
<td>0</td>
</tr>
<tr>
<td>1c</td>
<td>0</td>
</tr>
<tr>
<td>2a</td>
<td>0</td>
</tr>
<tr>
<td>2b</td>
<td>3</td>
</tr>
<tr>
<td>2c</td>
<td>0</td>
</tr>
<tr>
<td>3a</td>
<td>6</td>
</tr>
<tr>
<td>3b</td>
<td>20</td>
</tr>
<tr>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>5</td>
<td>1</td>
</tr>
</tbody>
</table>

**Comparison of LUS to a reference standard**

CT is highly sensitive for COVID-19 [13] and therefore is generally assumed to be the reference standard for LUS. However this assumption was challenged by Yang et al. [29] and Feng et al. [37] who concluded that LUS may in fact be more sensitive than CT.

The included studies are suggestive that LUS is highly sensitive for COVID-19. However sensitivity may be affected by factors including disease severity and scanning technique. Lu et al. [15] and Denina et al. [39] both found LUS to have greater sensitivity in more severe
disease. Regarding LUS technique, various protocols have been suggested ranging from a limited scan of just the anterolateral zones to a comprehensive ‘lawn-mower’ technique where the probe is slid along each intercostal space [44]. Given the disease is known to have a patchy distribution [18] it would be plausible that a more comprehensive protocol would be more sensitive however there is also evidence that LUS findings do not depend on the number of zones assessed [45].

PCR testing (in its current form) is highly specific but relatively insensitive [12]. LUS specificity may therefore be under-estimated in studies where LUS is compared only to PCR. For example in Bar et al. [35] specificity was 62% (vs PCR) but in Tung-Chen et al. [27] specificity was 79% (vs CT).

Operator experience may also affect specificity as an expert will be able to better correlate different LUS patterns with different disease processes. In Benchoufi et al. [30], specificity was 83% however this was based on the LUS being simply normal or pathologic. In Peyrony et al. [34] specificity was 89% however this was based on only the presence of bilateral B lines. A more nuanced LUS assessment may lead to greater specificity.

There may be particular LUS findings and patterns that are more specific for COVID-19. In Volpicelli et al. [46] the authors described a LUS artefact called ‘light beam’, defined as a broad, lucent, band-shaped, vertical artefact moving rapidly with sliding and arising from a regular pleural line. The authors stated that in a series of 100 patients (unpublished data) this finding was present in 48 of 49 patients with confirmed COVID-19 but in none of 12 patients with negative swabs and alternative diagnoses. Futhermore, Soldati et al. [47] argued that relative specificity can be attributed to the classic bilateral, patchy distribution with spared areas and multifocal confluent B lines (‘white lung’), especially in relatively young patients without a history of lung disease.
There is a spectrum of LUS findings in COVID-19 ranging from subtle to highly suggestive. Many studies have focused on LUS severity scores however in terms of diagnostic utility an assessment of likelihood rather than severity may be more useful. The differential diagnosis of each specific patient will also influence which LUS findings are most specific to COVID-19. If the alternative is pulmonary oedema, the presence of pleural thickening and irregularity is relatively specific for COVID-19. However if the alternative is pulmonary fibrosis this finding would not help to discriminate between these processes. In Hankins et al. [28], diagnostic accuracy was higher when LUS was interpreted by the treating clinician as opposed to being reviewed in isolation. This highlights the importance of integrating LUS findings with clinical findings. This Bayesian approach of combining a pre-test probability with point-of-care ultrasound findings is well described [48].

It should be noted that all of the included studies were conducted during a period of high disease prevalence and it is likely that measures of diagnostic accuracy will be affected by fluctuations in disease prevalence over time [49].

Serial LUS imaging

In Xing et al. [50], 20 adult patients with confirmed COVID-19 underwent 36 scans at various time intervals after onset of symptoms. The authors found that the extent of LUS findings reached a peak at the second week and then there was gradual improvement (but not complete resolution) until the fourth week.

In Shkoohi et al. [51], three physicians with confirmed COVID-19 monitored themselves at home and in all cases the LUS findings had resolved by day 14.

More information is urgently needed regarding the persistence of LUS findings as clinicians will be increasingly encountering patients who may have recently recovered from COVID-19.
Inter-observer agreement

Good inter-observer agreement of LUS findings was found between experts \(^{[35]}\) and between experts and novices \(^{[36]}\). However it was noted that removal of the practical element of novice training significantly reduced inter-observer agreement \(^{[28]}\). It was also noted that inter-observer agreement varied between different LUS findings, being highest for consolidation and lowest for pleural thickening \(^{[28]}\).

Inter-observer agreement will depend on the extent of training the novice has received and a wide array of training protocols have been described. In Benchoufi \(\textit{et al.}\) \(^{[30]}\), only 30 minutes of theoretical and 30 minutes of practical training was required. However it has previously been suggested that 25 scans are necessary to achieve competency in LUS \(^{[52]}\).

Further studies relating to inter-observer agreement are warranted however it appears the element of practical training is important. Novel technologies such as remote teleguidance could help to achieve this.

Technological innovation in LUS

New technologies may play an important role in augmenting the potential utility of LUS in COVID-19. Several avenues are currently being explored including artificial intelligence, deep learning, robotic LUS and contrast-enhanced LUS.

Dong \(\textit{et al.}\) \(^{[53]}\) stated that artificial intelligence or other quantitative image analysis methods were urgently needed to maximise the value of imaging modalities including LUS.

Roy \(\textit{et al.}\) \(^{[54]}\) created a deep model of automatic analysis from an annotated LUS data set and noted that this achieved ‘satisfactory results’ on all tasks including predicting disease severity.
Evans et al. [55] noted that robotic ultrasound equipment is being used at Zhejiang Provincial People’s Hospital in Hangzhou, China.

In Soldati et al. [56], three patients with confirmed COVID-19 received contrast-enhanced ultrasound (CEUS). Perfusion defects were noted within these lesions and the authors concluded that this was at least in part caused by ischaemic or necrotic changes rather than inflammation or atelectasis. This is consistent with the findings of Huang et al. [18] who noted the lack of colour Doppler signal within subpleural consolidations in COVID-19. If these peripheral lung lesions are in fact infarcts this may have major implications for clinical management and therefore this question deserves further attention.

**Special groups**

The issue of ionizing radiation is of great concern in children and pregnant women. Several small studies were identified that examined the utility of LUS in COVID-19 in these patient groups and were suggestive that LUS is as useful as it is in non-pregnant adults.

**Limitations**

The recent emergence and dynamic nature of the COVID-19 pandemic has led to the rapid publication of research and it is inevitable that new studies will continue to be released before this review is published.

A thorough and systematic literature search was performed including non-traditional sources (see Appendix I) however all relevant evidence may not have been identified due to publication bias and non-English language publications being excluded.

**Conclusion**

The evidence base for LUS in COVID-19 is rapidly expanding but the methodological quality of the identified studies was relatively low.
It is difficult to make a precise estimate of diagnostic accuracy of LUS in COVID-19 as both sensitivity and specificity may be influenced by various factors including disease severity, pre-existing lung disease, scanning protocol, operator experience, disease prevalence and the reference standard. However, LUS appears to be a highly sensitive and fairly specific test for COVID-19 in all ages and in pregnancy. LUS is probably more sensitive than CXR and possibly more sensitive than CT for COVID-19.

High quality research is needed to better define the utility of LUS in COVID-19 and thus inform clinicians of its most suitable role in a local context. Although the LUS findings in COVID-19 are now well described, further research is needed regarding the relative specificity of the various LUS findings and patterns. High quality, prospective studies assessing diagnostic accuracy in undifferentiated patients in an era of lower prevalence would also be of great value. The role of LUS in triage, prognostication, severity scoring, monitoring progression and guiding interventions has not yet been adequately explored. An understanding of the persistence of residual LUS findings post infection will be increasingly important going forwards. Larger studies assessing inter-observer agreement would both estimate reproducibility but may also help inform necessary training standards for novices. Further research into contrast-enhanced LUS and colour Doppler is warranted as this may significantly augment traditional LUS and contribute to a broader understanding of the disease process. International consensus is required regarding training standards, scanning protocols and an appropriate reference standard.
REFERENCES


Appendix I. Extended literature search

Specialised point-of-care ultrasound websites

- Zedu Ultrasound Training Solutions:

- Ultrasound G.E.L. Podcast: Gathering Evidence from the Literature:
  https://www.ultrasoundgel.org/articles

Specialty college websites

- Royal College of Emergency Medicine: https://www.rcemlearning.co.uk/research/

Pre-publication websites

- Figshare: https://figshare.com/browse

Social media

- Twitter hashtag: #pocusforcovid
Appendix II. Initial search

Databases to be searched:
1. Ovid MEDLINE® to June 13th 2020
2. Embase 1974 to 2020 June 13th 2020

Search strategy:
1. Lung OR chest OR thorax OR thoracic
2. Ultrasound OR ultrasonography OR sonography
3. COVID OR COVID-19 OR coronavirus OR SARS-CoV 2
4. 1 AND 2 AND 3
5. 4 AND remove duplicates
Appendix III. Second search

Databases to be searched:

1. Ovid MEDLINE® and Epub Ahead of Print, In-Process and Other Non-Indexed Citations, Daily and Versions 1946 to June 13\textsuperscript{th} 2020

2. Embase 1974 to 2020 June 13\textsuperscript{th}

3. Scopus

4. The Cochrane Library

5. The TRIP database

6. Google Scholar

7. www.clinicaltrials.gov

8. JBI Database of Systematic Reviews and Implementation Reports

9. Cochrane Database of Systematic Reviews

10. Cumulative Index to Nursing and Allied Health Literature (CINAHL)

11. Evidence for Policy and Practice Information (EPPI)

12. Epistemonikos

Second search strategy:

1. Lung OR chest OR thorax OR thoracic OR pulmonary

2. Ultrasound OR ultrasonography OR sonography OR ultrasonic

3. COVID OR COVID-19 OR coronavirus OR SARS

4. 1 AND 2 AND 3

5. 5 AND remove duplicates
## Appendix IV. Screening and selection tool

### LUS in COVID-19: Screening and Selection Tool

<table>
<thead>
<tr>
<th>Reviewer name:</th>
<th>Date:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title:</td>
<td></td>
</tr>
<tr>
<td>Author name:</td>
<td>Year:</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Inclusion Criteria</th>
<th>Exclusion Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnostic test:</td>
<td>LUS</td>
</tr>
<tr>
<td>Population:</td>
<td>Patients of any age with suspected or confirmed COVID-19</td>
</tr>
<tr>
<td>Concept:</td>
<td>Utility of LUS</td>
</tr>
<tr>
<td>Context:</td>
<td>Clinical management of COVID-19</td>
</tr>
<tr>
<td>Study design:</td>
<td>Case series</td>
</tr>
<tr>
<td></td>
<td>Experimental or observational studies</td>
</tr>
<tr>
<td></td>
<td>Reviews</td>
</tr>
<tr>
<td>Overall decision:</td>
<td>Included</td>
</tr>
</tbody>
</table>
## Appendix V. Study Characteristics and Results

<table>
<thead>
<tr>
<th>Author</th>
<th>Title</th>
<th>Date</th>
<th>Design</th>
<th>Sample size</th>
<th>Population</th>
<th>Outcomes &amp; Conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peng Q. et al.</td>
<td>Findings of lung ultrasonography of novel coronavirus pneumonia during the 2019–2020 epidemic</td>
<td>12/3/20</td>
<td>Single centre, retrospective, observational cohort</td>
<td>20</td>
<td>Adults with confirmed COVID-19</td>
<td>LUS findings included: Pleural line abnormalities B lines (focal, multifocal and confluent) Consolidations (from small to translobar with occasional air bronchograms) A lines appeared during recovery Pleural effusions were uncommon We consider that lung ultrasonography has major utility for management of COVID-19</td>
</tr>
<tr>
<td>Lomoro P. et al.</td>
<td>COVID-19 pneumonia manifestations at the admission on chest ultrasound, radiographs, and CT: single-center study and comprehensive radiologic literature review</td>
<td>1/4/20</td>
<td>Single centre, retrospective, observational cohort</td>
<td>32</td>
<td>Adults with confirmed COVID-19</td>
<td>LUS findings included diffuse B lines (100%) and subpleural consolidations (27%) LUS has an important role in the management of patients with SARS-CoV-2 allowing rapid diagnosis and monitoring of COVID-19 pneumonia and its evolution toward ARDS</td>
</tr>
<tr>
<td>Yasukawa K. &amp; Minami T.</td>
<td>Point-of-Care Lung Ultrasound Findings in Patients with Novel Coronavirus Disease (COVID-19) Pneumonia</td>
<td>24/4/20</td>
<td>Single centre, retrospective, observational cohort</td>
<td>10</td>
<td>Admitted adults with confirmed COVID-19</td>
<td>LUS findings included B lines and pleural line abnormalities (10/10) and subpleural consolidations (5/10) Point-of-care lung ultrasound has multiple advantages, including lack of radiation exposure and repeatability</td>
</tr>
<tr>
<td>Volpicelli G. et al.</td>
<td>What’s new in lung ultrasound during the covid-19 pandemic</td>
<td>4/5/20</td>
<td>Unpublished single centre, retrospective, observational cohort</td>
<td>n/a</td>
<td>n/a</td>
<td>Unpublished series of 100 patients revealed the presence of ‘light beams’ in 48 of the 49 patients with confirmed COVID-19. The same sign was never observed in 12 patients with alternative pulmonary diagnoses and negative swab test</td>
</tr>
</tbody>
</table>

Comparison of LUS to a reference standard (CT)
<table>
<thead>
<tr>
<th>Author(s)</th>
<th>Title</th>
<th>Study Design</th>
<th>Methodology</th>
<th>Sample Size</th>
<th>Results/Discussion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lu W. et al.</td>
<td>A Clinical Study of Noninvasive Assessment of Lung Lesions in Patients with Coronavirus Disease-19 (COVID-19) by Bedside Ultrasound</td>
<td>6/4/20</td>
<td>Single centre, blinded, retrospective cohort</td>
<td>30</td>
<td>Admitted adults with confirmed COVID-19 Moderate agreement between LUS and CT: kappa 0.53 Diagnostic accuracy varied with severity: Mild 77%, Moderate 77%, Severe 93% Average LUS scan time 5-8 min</td>
</tr>
<tr>
<td>Lyu G. et al.</td>
<td>Transthoracic Ultrasound Evaluation of Pulmonary Changes in COVID-19 Patients During Treatment Using Modified Protocols</td>
<td>10/4/20</td>
<td>Single centre, retrospective, observational cohort</td>
<td>8</td>
<td>Adults with confirmed severe or critical COVID-19 LUS findings included pleural line abnormalities (8/8), B lines (8/8), consolidations (3/8) and pleural effusion (1/8) LUS correlated closely with HRCT</td>
</tr>
<tr>
<td>Benchoufi M. et al.</td>
<td>Lung injury in patients with or suspected COVID-19: a comparison between lung ultrasound and chest CT-scanner severity assessments, an observational study</td>
<td>4/5/20</td>
<td>Multi-centre, prospective, blinded, observational study</td>
<td>107</td>
<td>Adults with suspected COVID-19 LUS Score showed good performance to predict CT severity assessment of COVID-19, AUC 0.93, Sensitivity 95%, Specificity 83% Good agreement between new trainee and expert, kappa 0.85-1 (when given 90m teaching &amp; 30m practice) Moderate agreement, kappa 0.62-0.81 (when only 30m teaching)</td>
</tr>
<tr>
<td>Tung-Chen Y. et al.</td>
<td>Correlation between chest CT and LUS in patients with COVID-19</td>
<td>12/5/20</td>
<td>Single centre, prospective, blinded trial</td>
<td>51</td>
<td>Adults presenting to ED with suspected COVID-19 Sensitivity 100% Specificity 79% AUC (ROC) 86% vs 63% LUS vs PCR for detection of CT abnormalities LUS presents similar accuracy compared to chest CT to detect lung abnormalities in COVID-19 patients.</td>
</tr>
<tr>
<td>Yang Y. et al.</td>
<td>Lung ultrasonography versus chest CT in COVID-19 pneumonia: a two-centered retrospective comparison study from China</td>
<td>25/5/20</td>
<td>Multi-centre, blinded, retrospective cohort</td>
<td>29</td>
<td>Admitted adults with confirmed COVID-19 pneumonia 340 positive regions on LUS vs 209 on CT LUS is more sensitive than chest CT in detecting lesions such as alveolar-interstitial disorders, consolidation and PE in patients with COVID-19 pneumonia</td>
</tr>
</tbody>
</table>
**Comparison of LUS to a reference standard (PCR)**

<table>
<thead>
<tr>
<th>Authors</th>
<th>Study Title</th>
<th>Methodology</th>
<th>Date</th>
<th>Setting</th>
<th>Participants</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Walsh P. et al.</td>
<td>Point of care lung ultrasound is useful when screening for CoVid-19 in Emergency Department patients.</td>
<td>Single centre, retrospective, observational cohort</td>
<td>9/6/20</td>
<td></td>
<td>49 Adults presenting to ED with suspected COVID-19</td>
<td>33% of symptomatic patients with normal vital signs had LUS findings consistent with COVID-19</td>
</tr>
<tr>
<td>Pebrony O. et al.</td>
<td>Accuracy of ED clinical findings for diagnosis of COVID-19</td>
<td>Single centre prospective trial</td>
<td>21/5/20</td>
<td></td>
<td>47 Adults presenting to ED with suspected COVID-19</td>
<td>Sensitivity 77%&lt;br&gt;Specificity 89%&lt;br&gt;Bilateral B-lines on lung ultrasound increased the likelihood of identifying COVID-19 inpatients presenting to ED</td>
</tr>
<tr>
<td>Bar S. et al.</td>
<td>The association of lung ultrasound images with COVID-19 infection in an emergency room cohort</td>
<td>Single centre, prospective, blinded trial</td>
<td>10/6/20</td>
<td></td>
<td>100 Non-pregnant adults without chronic interstitial lung disease presenting to ED with suspected COVID-19</td>
<td>The combination of clinical assessment and LUS had a sensitivity of 97% and specificity of 62% for COVID-19&lt;br&gt;The association of BLUE protocol lung ultrasound signs and qSOFA could facilitate more effective triage of patients presenting to ED with suspected COVID-19</td>
</tr>
</tbody>
</table>

**Serial LUS imaging**

<table>
<thead>
<tr>
<th>Authors</th>
<th>Study Title</th>
<th>Methodology</th>
<th>Date</th>
<th>Setting</th>
<th>Participants</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Soldati G. et al.</td>
<td>Contrast-Enhanced Ultrasound in Patients With COVID-19</td>
<td>Case series</td>
<td>23/4/20</td>
<td></td>
<td>3 Adults with confirmed COVID-19</td>
<td>Noted incomplete enhancement of consolidations suggesting ischaemia or necrosis</td>
</tr>
<tr>
<td>Dong D. et al.</td>
<td>The role of imaging in the detection and management of COVID-19: a review</td>
<td>Review</td>
<td>27/4/20</td>
<td></td>
<td>n/a</td>
<td>Artificial Intelligence or other quantitative image analysis methods are urgently needed to maximize the value of imaging in the management of COVID-19</td>
</tr>
<tr>
<td>Xing C. et al.</td>
<td>Lung ultrasound findings in patients with COVID-19 pneumonia</td>
<td>Single centre, retrospective, observational cohort</td>
<td>28/4/20</td>
<td></td>
<td>20 Admitted adults with confirmed moderate to critical COVID-19 pneumonia</td>
<td>100% B lines and irregular pleural line&lt;br&gt;50% consolidation&lt;br&gt;LUS findings peaked in 2nd week, some resolution by 4th week</td>
</tr>
<tr>
<td>Shokoohi H. et al.</td>
<td>Lung ultrasound monitoring in patients with COVID-19 on home isolation</td>
<td>Case series</td>
<td>28/5/20</td>
<td></td>
<td>3 Physician patients with confirmed COVID-19</td>
<td>LUS findings began at symptom onset and resolved within 14 days</td>
</tr>
</tbody>
</table>

**Technological innovation in LUS**
<table>
<thead>
<tr>
<th>Author(s)</th>
<th>Title</th>
<th>Date</th>
<th>Type</th>
<th>n/a</th>
<th>n/a</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evans K. et al.</td>
<td>Sonography of the Lungs: Diagnosis and Surveillance of Patients With COVID-19</td>
<td>21/4/20</td>
<td>Article</td>
<td>n/a</td>
<td>n/a</td>
<td>Robotic ultrasound equipment is being used at Zhejiang Provincial People’s Hospital in Hangzhou, China</td>
</tr>
<tr>
<td>Roy S. et al.</td>
<td>Deep learning for classification and localization of COVID-19 markers in point-of-care lung ultrasound</td>
<td>14/5/20</td>
<td>Article</td>
<td>n/a</td>
<td>n/a</td>
<td>Created a deep model of automatic analysis from an annotated LUS data set and noted that this achieved ‘satisfactory results’ on all tasks including predicting disease severity</td>
</tr>
<tr>
<td>Buonsenso D. et al.</td>
<td>Clinical Role of Lung Ultrasound for the Diagnosis and Monitoring of COVID-19 Pneumonia in Pregnant Women</td>
<td>26/4/20</td>
<td>Single centre, retrospective, observational cohort</td>
<td>4</td>
<td></td>
<td>4/4 had B lines and pleural irregularity LUS was more sensitive than CXR</td>
</tr>
<tr>
<td>Giannini A. et al.</td>
<td>Lung ultrasound for pregnant women admitted to ICU for COVID-19 pneumonia</td>
<td>29/5/20</td>
<td>Single centre, retrospective, observational cohort</td>
<td>5</td>
<td></td>
<td>LUS findings substantially overlapped with those described in COVID-19 LUS can be an effective tool in monitoring for deterioration</td>
</tr>
<tr>
<td>Yassa M. et al.</td>
<td>Lung ultrasound can influence the clinical treatment of pregnant women with COVID-19</td>
<td>1/6/20</td>
<td>Single centre, retrospective, observational cohort</td>
<td>8</td>
<td></td>
<td>7/8 women showed significant lung involvement on LUS Treatment was commenced or changed in 87.5% of patients</td>
</tr>
<tr>
<td>Musolino A. et al.</td>
<td>Lung ultrasound in children with covid-19: preliminary findings</td>
<td>24/4/20</td>
<td>Multi-centre, retrospective, observational cohort</td>
<td>10</td>
<td></td>
<td>LUS, was useful in diagnosing and monitoring pediatric COVID-19 pneumonia</td>
</tr>
<tr>
<td>Feng X. et al.</td>
<td>Application of LUS in diagnosis of neonatal coronavirus pneumonia</td>
<td>2/5/20</td>
<td>Single centre, retrospective, observational cohort</td>
<td>5</td>
<td></td>
<td>5/5 Diffuse B lines and pleural irregularity 2/5 CTs were normal LUS is superior to CXR and CT</td>
</tr>
<tr>
<td>Gregorio-Hernandez R. et al.</td>
<td>Point-of-care lung ultrasound in three neonates with COVID-19</td>
<td>5/6/20</td>
<td>Single centre, retrospective, observational cohort</td>
<td>3</td>
<td></td>
<td>LUS showed B lines, consolidation and spared areas LUS could be of value when managing COVID-19 in neonates</td>
</tr>
<tr>
<td>Author(s)</td>
<td>Title of the Study</td>
<td>Date</td>
<td>Study Design</td>
<td>Study Population</td>
<td>Results</td>
<td></td>
</tr>
<tr>
<td>----------</td>
<td>--------------------</td>
<td>------</td>
<td>--------------</td>
<td>------------------</td>
<td>---------</td>
<td></td>
</tr>
<tr>
<td>Denina M. et al.</td>
<td>Lung Ultrasound in Children With COVID-19</td>
<td>21/4/20</td>
<td>Single centre, retrospective, observational cohort</td>
<td>8 Admitted children with confirmed COVID-19 pneumonia</td>
<td>Sensitivity 63% 25% in mild (n=4) 100% in moderate (n=2) 100% in severe (n=2) Ultrasound may be a reasonable method to detect lung abnormalities in children with COVID-19</td>
<td></td>
</tr>
</tbody>
</table>

### Reviews

<table>
<thead>
<tr>
<th>Author(s)</th>
<th>Title of the Study</th>
<th>Date</th>
<th>Study Type</th>
<th>Number of Studies</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Convissar D. et al.</td>
<td>Application of Lung Ultrasound during the COVID-19 Pandemic: A Narrative Review</td>
<td>30/4/20</td>
<td>Narrative review</td>
<td>5 studies</td>
<td>LUS has a potential role for portable point-of-care ultrasound (POCUS) as a safe and effective bedside option in the initial evaluation, management, and monitoring of disease progression in patients with confirmed or suspected COVID-19 infection</td>
</tr>
<tr>
<td>Lepri G. et al.</td>
<td>The emerging role of lung ultrasound in COVID-19 pneumonia</td>
<td>7/5/20</td>
<td>Narrative review</td>
<td>4 studies</td>
<td>LUS will likely play an important role in the management of COVID-19 patients from identification of specific abnormalities corresponding to definite pneumonia phases and CT scans findings.</td>
</tr>
<tr>
<td>Sultan L. et al.</td>
<td>A review of early experience in lung ultrasound (LUS) in the diagnosis and management of COVID-19</td>
<td>15/5/20</td>
<td>Narrative review</td>
<td>14 studies</td>
<td>Although the number of studies to date are limited, LUS findings have demonstrated high diagnostic sensitivity and accuracy, comparable to those of chest CT scans.</td>
</tr>
<tr>
<td>Mohamed M. et al.</td>
<td>Frequency of Abnormalities Detected by PoCUS LUS in Symptomatic COVID-19 Patients: Systematic Review and Meta-Analysis</td>
<td>2/6/20</td>
<td>Systematic review and meta-analysis</td>
<td>7 studies 122 patients</td>
<td>LUS findings included B pattern 0.97 (0.94-1) Pleural abnormality 0.7 (0.13-1) Pleural thickening 0.54 (0.11-0.95) Consolidations 0.39 (0.21-0.58) Pleural effusion 0.14 (0-0.37) POCUS will likely play a vital role in the future triage, diagnosis, management, and follow-up of COVID-19 patients</td>
</tr>
</tbody>
</table>